[go: up one dir, main page]

RU2000125889A - SUBSTITUTED BISINDOLYMALEIMIDES INTENDED TO INHIBIT CELL PROLIFERATION - Google Patents

SUBSTITUTED BISINDOLYMALEIMIDES INTENDED TO INHIBIT CELL PROLIFERATION

Info

Publication number
RU2000125889A
RU2000125889A RU2000125889/04A RU2000125889A RU2000125889A RU 2000125889 A RU2000125889 A RU 2000125889A RU 2000125889/04 A RU2000125889/04 A RU 2000125889/04A RU 2000125889 A RU2000125889 A RU 2000125889A RU 2000125889 A RU2000125889 A RU 2000125889A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
compound
denotes
formula
intended
Prior art date
Application number
RU2000125889/04A
Other languages
Russian (ru)
Other versions
RU2208612C2 (en
Inventor
Урваши Хоода ДИНГРА
Донна Мэри ХЬЮРИН
Джун Ки
Джузеппе Федерико УЭБЕР
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2000125889A publication Critical patent/RU2000125889A/en
Application granted granted Critical
Publication of RU2208612C2 publication Critical patent/RU2208612C2/en

Links

Claims (8)

1. Соединение формулы
Figure 00000001

где R1 обозначает водород и R2 обозначает метил, или R1 обозначает метил и R2 обозначает водород, или R1 обозначает гидроксиметил и R2 обозначает метил,
а также его фармацевтически приемлемые пролекарства или фармацевтически приемлемые соли.
1. The compound of the formula
Figure 00000001

where R 1 denotes hydrogen and R 2 denotes methyl, or R 1 denotes methyl and R 2 denotes hydrogen, or R 1 denotes hydroxymethyl and R 2 denotes methyl,
as well as its pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts.
2. Соединение по п. 1 формулы
Figure 00000002

и его фармацевтически приемлемые пролекарства или фармацевтически приемлемые соли этого соединения.
2. The compound according to claim 1 of formula
Figure 00000002

and its pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts of this compound.
3. Соединение формулы
Figure 00000003

и его фармацевтически приемлемые пролекарства или фармацевтически приемлемые соли этого соединения.
3. The compound of the formula
Figure 00000003

and its pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts of this compound.
4. Соединение формулы
Figure 00000004

и его фармацевтически приемлемые пролекарства или фармацевтически приемлемые соли этого соединения.
4. The compound of the formula
Figure 00000004

and its pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts of this compound.
5. Фармацевтическая композиция, включающая соединение формулы
Figure 00000005

где R1 обозначает водород и R2 обозначает метил, или R1 обозначает метил и R2 обозначает водород, или R1 обозначает гидроксиметил и R2 обозначает метил,
или его фармацевтически приемлемую соль или пролекарство этого соединения и фармацевтически приемлемый носитель.
5. A pharmaceutical composition comprising a compound of formula
Figure 00000005

where R 1 denotes hydrogen and R 2 denotes methyl, or R 1 denotes methyl and R 2 denotes hydrogen, or R 1 denotes hydroxymethyl and R 2 denotes methyl,
or its pharmaceutically acceptable salt or prodrug of this compound and a pharmaceutically acceptable carrier.
6. Соединение по любому из пп. 1-4, предназначенное для применения в качестве противоопухолевого лекарства. 6. The compound according to any one of paragraphs. 1-4, intended for use as an anticancer drug. 7. Применение соединения по любому из пп. 1-4 для лечения твердых опухолей или для приготовления фармацевтических композиций. 7. The use of compounds according to any one of paragraphs. 1-4 for the treatment of solid tumors or for the preparation of pharmaceutical compositions. 8. Соединения, композиции, способы и применения как они представлены в данном описании. 8. Compounds, compositions, methods and uses as presented in this specification.
RU2000125889/04A 1998-03-17 1999-03-10 Substituted bis-indolimaleimides designated for inhibition of cell proliferation RU2208612C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7833198P 1998-03-17 1998-03-17
US60/078,331 1998-03-17

Publications (2)

Publication Number Publication Date
RU2000125889A true RU2000125889A (en) 2002-09-27
RU2208612C2 RU2208612C2 (en) 2003-07-20

Family

ID=22143350

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000125889/04A RU2208612C2 (en) 1998-03-17 1999-03-10 Substituted bis-indolimaleimides designated for inhibition of cell proliferation

Country Status (33)

Country Link
US (1) US6048887A (en)
EP (1) EP1064279B1 (en)
JP (2) JP5026633B2 (en)
KR (1) KR100659411B1 (en)
CN (1) CN1127500C (en)
AR (1) AR018162A1 (en)
AT (1) ATE243693T1 (en)
AU (1) AU755673B2 (en)
BR (1) BR9908882A (en)
CA (1) CA2322689C (en)
CO (1) CO5070675A1 (en)
CZ (1) CZ299068B6 (en)
DE (1) DE69909068T2 (en)
DK (1) DK1064279T3 (en)
ES (1) ES2203111T3 (en)
HR (1) HRP20000585B1 (en)
HU (1) HU228831B1 (en)
ID (1) ID26353A (en)
IL (1) IL138247A (en)
MA (1) MA26613A1 (en)
MY (1) MY121046A (en)
NO (1) NO320306B1 (en)
NZ (1) NZ506476A (en)
PE (1) PE20000340A1 (en)
PL (1) PL195323B1 (en)
PT (1) PT1064279E (en)
RS (1) RS49965B (en)
RU (1) RU2208612C2 (en)
SA (1) SA99191295B1 (en)
TR (1) TR200002580T2 (en)
TW (1) TW539676B (en)
WO (1) WO1999047518A1 (en)
ZA (1) ZA992072B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138247A (en) * 1998-03-17 2005-08-31 Hoffmann La Roche Substituted bisindolymaleimides for the inhibition of cell proliferation and pharmaceutical compositions comprising them
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6559164B1 (en) 1999-10-12 2003-05-06 Hoffmann-La Roche Inc. Substituted pyrroles suitable for continuous infusion
NZ518038A (en) * 1999-10-12 2004-02-27 F Substituted pyrroles as antiproliferative agents for the treatment of cancer
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
US6281356B1 (en) * 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
US6326501B1 (en) * 2000-04-19 2001-12-04 Hoffmann-La Roche Inc. Methylation of indole compounds using dimethyl carbonate
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US6482847B2 (en) 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6469179B1 (en) 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
WO2008117935A1 (en) * 2007-03-28 2008-10-02 Industry-Academic Cooperation Foundation, Yonsei University Nk cell activating molecules, nk cells and pharmaceutical compositons comprising the same
CN102924437B (en) * 2012-11-19 2014-07-02 东华大学 3-piperazine-4-indol maleimide compound and preparation and application thereof
WO2019000224A1 (en) * 2017-06-27 2019-01-03 中国海洋大学 Bisindolylmaleimide derivative and preparation method and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (en) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituted pyrroles, their use for preparing medicaments and medicaments based thereon
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
ATE456367T1 (en) * 1993-12-23 2010-02-15 Lilly Co Eli PROTEIN KINASE C INHIBITORS
PE91698A1 (en) * 1996-07-29 1998-12-24 Hoffmann La Roche SUBSTITUTED PYRROLES
PE91598A1 (en) * 1996-07-29 1998-12-24 Hoffmann La Roche SUBSTITUTED PYRROLES
PE91498A1 (en) * 1996-07-29 1998-12-22 Hoffmann La Roche SUBSTITUTED PYRROLES
IL138247A (en) * 1998-03-17 2005-08-31 Hoffmann La Roche Substituted bisindolymaleimides for the inhibition of cell proliferation and pharmaceutical compositions comprising them

Similar Documents

Publication Publication Date Title
RU2000125889A (en) SUBSTITUTED BISINDOLYMALEIMIDES INTENDED TO INHIBIT CELL PROLIFERATION
RU2221798C2 (en) Imidazonaphthyridines, pharmaceutical composition based on thereof, method for stimulating biosynthesis of cytokine and intermediate compounds
RU94040390A (en) Derivatives of vinyleneazaindole, method of their synthesis, pharmaceutical composition
CA2290918A1 (en) Heteroaromatic bicyclic derivatives useful as anticancer agents
CA2392973A1 (en) Benzoimidazole derivatives useful as antiproliferative agents
MX2010003868A (en) Chiral cis-imidazolines.
RU94030812A (en) DERIVATIVES OF PHOSPHONOANATIC ACID, METHOD OF THEIR PRODUCTION AND CONTAINING THESE COMPOUNDS PHARMACEUTICAL COMPOSITIONS
RU2008141850A (en) LIQUID PHARMACEUTICAL PRODUCT WITH IMMEDIATE RELEASE
TR200103395T2 (en) 13-methyl erythromycin derivatives.
RU2002123641A (en) S-4 carbonate-containing taxanes
RU2002100058A (en) 1-Methylcarbapenem Crystal Derivatives
EE200000472A (en) Antineoplastic agents
RU2002130247A (en) OXADIAZOLE DERIVATIVES WITH ANTITUMER ACTION
JP2002506864A5 (en)
RU94039545A (en) New adenosine derivatives, methods of their synthesis, pharmaceutical compositions based on thereof, methods of preparing pharmaceutical compositions and their use
SE0302570D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1109560A4 (en) Compounds useful as aicarft inhibitors
EA200101241A1 (en) INDOLA DERIVATIVES
RU2220965C2 (en) Sulfonamide-substituted compounds and pharmaceutical composition based on thereof
EA200700144A1 (en) PYRIDOPYRIMIDINE DERIVATIVES, THEIR RECEIVING, THEIR APPLICATION IN THERAPY
RU2004133388A (en) NEW SALTS
RU94021365A (en) DERIVATIVES OF METHYLPIPERAZINAZEPENINE, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND USE OF DERIVATIVES AS A PHARMACEUTICAL ACTIVE SUBSTANCE
RU2004109817A (en) AMINOPYRROLEN DERIVATIVES AS ANTI-INFLAMMATORY PRODUCTS
JP2003535868A5 (en)
EA200100725A3 (en) Benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them